{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-060140","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2023-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.300291+00:00","generated_at":"2026-06-12T23:48:40.865620+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ABVC BioPharma prices $1.75M registered direct offering of 500,000 shares/pre-funded warrants at $3.50/share","bullets":["Gross proceeds of $1.75M from sale of 300,000 shares and 200,000 pre-funded warrants at $3.50/share.","Single institutional investor; closing expected July 31, 2023.","Net proceeds for R&D, working capital, and possible debt repayment.","Wilmington Capital Securities acting as exclusive placement agent.","Offering made under effective shelf registration statement (File No. 333-260588)."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-060140","json":"https://secwatch.observer/filing/0001213900-23-060140.json","markdown":"https://secwatch.observer/filing/0001213900-23-060140.md","text":"https://secwatch.observer/filing/0001213900-23-060140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023060140/0001213900-23-060140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023060140/ea182424-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T23:48:40.865620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"174ebede7eca3a89ca3f370f076a3ebc3457322e","claim":"ABVC BIOPHARMA, INC. entered into Securities Purchase Agreement with certain investors (the \"Purchasers\") valued at gross proceeds of $1,750,000 (effective 2023-07-27).","evidence_excerpt":"ABVC BioPharma, Inc. (the “ Company ”) and certain investors (the “ Purchasers ”) entered into that certain securities purchase agreement on July 27, 2023 (the “ Purchase Agreement ”) relating to the offer and sale of 300,000 shares of common stock (the “ Shares ”), par value $0.001 per share (the “ Common Stock ”) and 200,000 pre-funded warrants, at an exercise price of $0.01 per share (the “ Pre-funded Warrants ”), in a registered direct offering (the “ Offering ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023060140/0001213900-23-060140-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors (the \"Purchasers\")"},{"label":"Value","value":"gross proceeds of $1,750,000"},{"label":"Effective","value":"2023-07-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}